Skip to main content
LM

Liberate Medical

Liberate Medical develops the VentFree Respiratory Muscle Stimulator, a non-invasive device that uses electrical stimulation to contract expiratory muscles during mechanical ventilation. This therapy begins on day one of ventilation to maintain muscle activity and potentially reduce respiratory muscle atrophy. The intended outcome is to decrease the duration patients require mechanical ventilation support.

Crestwood, United StatesFounded 2013151K+ followers
Updated 4 months ago

Funding

$6.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

US
Funding rounds are not available yet.

Founders

Product

Problem

Prolonged mechanical ventilation can lead to expiratory muscle atrophy, which is associated with weaning failure and delayed extubation. This condition contributes to increased hospital mortality, morbidity, and post-discharge complications for critically ill patients.

Solution

Liberate Medical offers the VentFree Respiratory Muscle Stimulator, a non-invasive device designed to mitigate expiratory muscle atrophy in mechanically ventilated patients. The system utilizes neuromuscular electrical stimulation to contract abdominal muscles in synchrony with exhalation, maintaining muscle activity from the initial day of ventilation. This approach aims to support earlier weaning from respiratory support and potentially reduce the overall duration of mechanical ventilation. The device is designed for ease of use, allowing therapy to commence even when patients are sedated or experiencing delirium.

Target Audience

The primary target audience includes hospitals and intensive care units that manage patients requiring mechanical ventilation, particularly those at risk of respiratory muscle atrophy and prolonged ventilator dependence.

Features

  • Non-invasive neuromuscular electrical stimulation to contract expiratory muscles.
  • Synchronized stimulation with the patient's exhalation cycle.
  • Proprietary technology for muscle activation during mechanical ventilation.
  • CE marked for sale within the European Economic Area.
  • Emergency Use Authorization in the USA for reducing disuse atrophy of abdominal wall muscles.
  • Designed for initiation of therapy from day one of mechanical ventilation.
This profile is AI-generated and may contain inaccuracies.